Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E2086 in Adult Subjects With Narcolepsy Type 1
NCT06462404Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jun 2024
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of E2086 in narcolepsy type 1 (NT1) (10 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Mean Sleep Latency as Assessed by the Maintenance of Wakefulness Test at Day 17. Started Jun 2024; status: completed.
02
Drugs
E2086
03
Conditions
narcolepsy type 1 (NT1)
Beyond the preview
Go deeper on NCT06462404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06462404.